The Role of Hepatocyte Nuclear Factor-1β in the Pathogenesis of Clear Cell Carcinoma of the Ovary

2009 ◽  
Vol 19 (3) ◽  
pp. 471-479 ◽  
Author(s):  
Hiroshi Kobayashi ◽  
Yoshihiko Yamada ◽  
Seiji Kanayama ◽  
Naoto Furukawa ◽  
Taketoshi Noguchi ◽  
...  

Problem:Clear cell carcinoma (CCC) of the ovary has a number of features distinguishing it from other epithelial ovarian carcinomas (EOC) because of its characteristic histology and biology, frequent concurrence with endometriotic lesion, and highly chemoresistant nature resulting in an extremely poor prognosis. The incidence of CCC has been steadily increasing in Japan. They comprise approximately 20% of all EOC. Understanding the mechanisms of CCC development and elucidating pathogenesis and pathophysiology are intrinsic to prevention and effective therapies for CCC.Method of study:This article reviews the English language literature for biology, pathogenesis, and pathophysiological studies on endometriosis-associated EOC. Several data are discussed in the context of endometriosis and CCC biology.Results:Recent studies based on genome-wide expression analysis technology have noted specific expression of hepatocyte nuclear factor-1β (HNF-1β) in endometriosis and CCC, suggesting that early differentiation into the clear cell lineage takes place in the endometriosis. The HNF-1β-dependent pathway of CCC will be discussed, which are providing new insights into regulation of apoptosis and glycogen synthesis and resistance of CCC to anticancer agents.Conclusions:This review summarizes recent advances in the HNF-1β and its target genes; the potential challenges to the understanding of carcinogenesis, pathogenesis, and pathophysiology of CCC; and a possible novel model is proposed.

2013 ◽  
Vol 54 (1) ◽  
pp. 35-49 ◽  
Author(s):  
Takako Okamoto ◽  
Masaki Mandai ◽  
Noriomi Matsumura ◽  
Ken Yamaguchi ◽  
Eiji Kondoh ◽  
...  

2008 ◽  
Vol 21 (9) ◽  
pp. 1075-1083 ◽  
Author(s):  
Lisa Kim ◽  
Jie Liao ◽  
Meng Zhang ◽  
Mark Talamonti ◽  
David Bentrem ◽  
...  

2019 ◽  
Vol 24 (10) ◽  
pp. 1273-1283 ◽  
Author(s):  
Kazuki Takasaki ◽  
Morikazu Miyamoto ◽  
Masashi Takano ◽  
Hiroaki Soyama ◽  
Tadashi Aoyama ◽  
...  

2008 ◽  
Vol 18 (5) ◽  
pp. 937-942 ◽  
Author(s):  
M. Takano ◽  
T. Sugiyama ◽  
N. Yaegashi ◽  
M. Sakuma ◽  
M. Suzuki ◽  
...  

Clear cell carcinoma (CCC) of the ovary has been recognized to show resistance to anticancer agents in the first-line chemotherapy. Our aim was to evaluate the effect of second-line chemotherapy in a retrospective study. A total of 75 patients diagnosed with CCC and treated between 1992 and 2002 in collaborating hospitals were reviewed. Criteria for the patients' enrollment were 1) diagnosis of pure-type CCC at the initial operation, 2) treatment after one systemic postoperative chemotherapy, 3) measurable recurrent or refractory tumor, 4) at least two cycles of second-line chemotherapy and assessable for the response, and 5) adequate clinical information. Regimens of first-line chemotherapy were conventional platinum-based therapy in 33 cases, paclitaxel plus platinum in 24 cases, irinotecan plus platinum in 9 cases, and irinotecan plus mitomycin C in 7 cases. Treatment-free periods were more than 6 months in 24 cases (group A) and less than 6 months in 51 cases (group B). In group A, response was observed in two cases (8%): one with conventional platinum therapy and another with irinotecan plus platinum. In group B, three cases (6%) responded: two with platinum plus etoposide and one case with irinotecan plus platinum. Median overall survival was 16 months in group A and 7 months in group B (P= 0.04). These findings suggest recurrent or resistant CCC is extremely chemoresistant, and there is only small benefit of long treatment-free period in CCC patients. Another strategy including molecular-targeting therapy is warranted for the treatment of recurrent or refractory CCC.


2002 ◽  
Vol 93 (6) ◽  
pp. 723-728 ◽  
Author(s):  
Hiroaki Itamochi ◽  
Junzo Kigawa ◽  
Habiba Sultana ◽  
Takahiro Iba ◽  
Ryoji Akeshima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document